The pharmaceutical company Spark Therapeutics recently announced FDA approval1,2 of a gene therapy known as Luxturna, which has been shown to improve vision in patients with an extremely rare inherited eye disease caused by mutations in the gene RPE65.
December 27th, 2017
June 1st, 2017Clinically Focused Molecular Investigation of 1000 Consecutive Families with Inherited Retinal Disease
A team of WIVR investigators undertook the molecular investigation of 1000 consecutive families with inherited retinal disease. This study validated the clinically directed tiered testing strategy employed by the Carver Nonprofit Genetic Testing Laboratory
March 30th, 2017
A new WIVR study shows that high-resolution 3D-printing can be used to create protective scaffolds that also align patient-specific retinal precursor cells for delivery to the sub-retinal space.